News - Page 17

Biotech Breakthrough: How Viking Therapeutics Aims to Transform Metabolic Disease Treatment

Viking Therapeutics is focused on treating metabolic and endocrine diseases with innovative approaches. The flagship drug, VK2735, targets obesity and type 2 diabetes by engaging GLP-1 and GIP receptors, showing rapid weight loss in Phase 2 trials. VK2735 offers both injectable and

15. April 2025

Business·Economy·Finance·Market·News·Opportunities

The Surprising Opportunities Amidst the Predicted 2025 Economic Storm

Expect volatility in 2025 with inflation, market fluctuations, and evolving global trade strategies. Despite societal turmoil akin to the 1960s, an economic boom driven by innovation and technology is anticipated. Artificial intelligence is identified as a disruptive yet transformative force, particularly in

11. March 2025

Business·Cybersecurity·Finance·Market·News·Technology

A Billionaire’s Bet: The Rising Star in Cybersecurity You Can’t Ignore

The global cybersecurity market is projected to grow at a 12.9% CAGR from 2025 to 2030 due to escalating digital threats. A10 Networks, Inc. (NYSE:ATEN) positions itself as a key player in the cybersecurity sector with secure application delivery and DDoS defense

10. March 2025

Business·Economy·Investment·Market·News·Technology

Alibaba’s Towering Presence in a Global Investment Landscape

Alibaba Group Holding Limited is a standout entity amid global market fluctuations, showcasing innovation and potential in 2025. US-China trade tensions mark the year, but Alibaba thrives with strong stock performance, reflecting a market cap of around $333.3 billion. The company focuses

10. March 2025

Business·Finance·Healthcare·Investment·Market·News

The Hidden Gem Among Healthcare Giants: Why Merck & Co. is a Hedge Fund Favorite

Merck & Co., Inc. (NYSE:MRK) is highlighted as a stable and growth-oriented investment within the volatile stock market, driven by its pioneering efforts in healthcare. KEYTRUDA, Merck’s leading oncology product, saw a 21% increase in sales in the last quarter of 2024,

10. March 2025

Autonomous Vehicles·Finance·Market·Nasdaq Composite·News·Stock Market·Technology

Can Nvidia Reach New Heights in the Face of Market Uncertainty?

Nvidia stands at a crossroads of opportunity and challenge amid current market volatility. Despite a recent market correction, Nvidia continues to drive innovation, leading the AI revolution with its pioneering GPU technology. Key to Nvidia’s competitive edge is its CUDA software, which

10. March 2025

Artificial Intelligence·Business·Market·News·Technology

Meta’s Ascension: How AI is Propelling This Tech Titan to New Heights

Meta Platforms, Inc. achieved a 22% revenue increase in 2024, doubling the digital advertising industry’s growth rate through AI-driven strategies. AI advancements led to a 32% boost in advertiser ROI and a 17% reduction in customer acquisition costs, driving advertisers to Meta’s

10. March 2025

Finance·Investing·Market·News·Stock Market

Rumble’s Ownership Tug-of-War: How Retail Investors and Insiders Shape Its Future

Retail investors hold 42% of Rumble Inc.’s shares, positioning them as pivotal players in the company’s strategic direction. Insiders account for a significant 30% ownership, directly influencing the company’s path with their active engagement as executives and board members. The top five

10. March 2025

Biotechnology·Investment·Market·News·Pharmaceuticals

Arrowhead Pharmaceuticals Faces Setback as RNA Therapeutic Data Raises Investor Eyebrows

Arrowhead Pharmaceuticals faces challenges with their RNA interference drug, ARO-C3, for complement-mediated renal diseases. The drug achieved a significant 89% reduction in C3 levels, indicating potential transformative effects and the possibility of less frequent dosing. Market response was negative, with Arrowhead’s stock

10. March 2025

Business·Economy·Finance·Market·News·Stocks·Trading·Value Stocks

The Market’s Roller Coaster: Discover the Stocks Defying the Downturn

Regeneron Pharmaceuticals saw a significant surge, gaining 4% per share, driven by promising results from a joint trial with Sanofi for Dupixent, targeting a severe autoimmune disease. Biogen emerged as a value play with its stock rising due to competitive valuation and

10. March 2025

Finance·Market·News·Regulation·Stocks·Trading

From Disruptor to Distress: Robinhood’s Ongoing Regulatory Turmoil

Robinhood’s stock price has dropped by 13% due to regulatory challenges and operational issues. The company agreed to a $29.8 million settlement with Finra for failures in its clearing technology and AML programs. A practice called “collaring” was poorly communicated to users,

10. March 2025